Skip to content
Exits and Outcomes
Sign In
Subscribe
Digital health research, news, and analysis from Brian Dolan.
$200/year or
consider an Enterprise subscription
.
Prescription Digital Therapeutics
All Newsletters
214 articles
19 of 22
AstraZeneca’s digital health strategy. Pear and Cognoa studies.
4.03.20
7
min. Read
Orexo prices DTx at $600 to $1,000. Pear: $1,000 to $1,600.
3.27.20
5
min. Read
Genentech-Roche VR for autism. FDA’s new remote monitoring waiver.
3.20.20
7
min. Read
Verily paid Sanofi $122M. ResMed MitiGait. Happify Kopa.
3.12.20
6
min. Read
FDA asks Congress for new SaMD pathway. Headspace $93M.
2.14.20
6
min. Read
Google’s EHR patient notification idea. Bayer-One Drop. Novartis-Pear.
2.07.20
6
min. Read
M&A multiples. Verily FDA. Hires: Otsuka, Astellas, Sanofi, Sandoz.
1.24.20
4
min. Read
Pear oncology. Omada schizophrenia. Noom’s $247M.
1.17.20
5
min. Read
AstraZeneca DTx. Virgin Pulse takes on Omada.
1.10.20
6
min. Read
When will DTx go DTC like Ro, Hims? Pear early revenue predictions.
1.03.20
5
min. Read
1 of 22